Highly lauded celiac disease clinician joins the SAB of ImmunogenX
ImmunogenX is pleased to announce the addition of Markku Mäki, MD, PhD to the Scientific Advisory Board of ImmunogenX. Dr. Mäki is a Professor (Emeritus) at the University of Tampere and presently Research Director at the Tampere University Hospital, Tampere, Finland. He has an extensive track record of leadership in celiac disease research. Dr. Mäki’s research has been inspired by the needs of the celiac sufferers; he has also been the President of the Finnish Celiac Society. Lately, Professor Maki has been involved in novel celiac disease drug trials where he is especially interested in outcome measurement development. In 2010, Professor Mäki received the Wm. K. Warren Jr. Prize in Celiac Disease in Clinical/Translational Research, San Diego, USA. Dr. Mäki is a permanent member of the Finnish Academy of Science and Letters and the President of Finland granted him the honor of Knight, First Class, of the Order of the White Rose of Finland in 2006.
Dr. Jennifer Sealey-Voyksner, ImmunogenX CSO remarks “Dr. Mäki is a world renowned clinician studying celiac disease and has extensive experience in clinical trial design that is key to the future development of our lead therapeutic treatment latiglutenase. Dr. Mäki was the principal investigator for the first efficacy trials for latiglutenase that provided ground breaking results demonstrating histologic protection to a gluten challenge. His knowledge of and faith in latiglutenase gives us great confidence that we will successfully bring this drug to market and help celiac disease patients from the suffering they incur.”
ImmunogenX is preparing for a final Phase 2 trial for latiglutense, an orally administered drug therapy, that is taken with meals and degrades gluten that is inadvertently ingested by individuals with celiac disease maintaining a gluten-free diet.
About ImmunogenX
ImmunogenX (a subsidiary of Immunogenics LLC) is a clinical-stage biotherapeutics company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research. The company is developing Latiglutenase (formerly ALV003) for celiac disease therapy. ImmunogenX is also developing a minimally-invasive diagnostic tool for celiac disease management (CypCelTM) based on a clinically relevant metabolic marker compound that can assess the state of recovery of a celiac patient adhering to a gluten-free diet or other treatment. For food safety, ImmunogenX is pioneering advanced mass spectrometry methods to identify and measure physiologically relevant gluten peptide sequences found in wheat, barley, and rye.
www.immunogenx.com
For further information please contact
Matthew Dickason, COO 949 679-0900 mdickason@immunogenx.com
News Release
Newport Beach, CA – October 12, 2017
ImmunogenX is pleased to announce the addition of Markku Mäki, MD, PhD to the Scientific Advisory Board of ImmunogenX. Dr. Mäki is a Professor (Emeritus) at the University of Tampere and presently Research Director at the Tampere University Hospital, Tampere, Finland. He has an extensive track record of leadership in celiac disease research. Dr. Mäki’s research has been inspired by the needs of the celiac sufferers; he has also been the President of the Finnish Celiac Society. Lately, Professor Maki has been involved in novel celiac disease drug trials where he is especially interested in outcome measurement development. In 2010, Professor Mäki received the Wm. K. Warren Jr. Prize in Celiac Disease in Clinical/Translational Research, San Diego, USA. Dr. Mäki is a permanent member of the Finnish Academy of Science and Letters and the President of Finland granted him the honor of Knight, First Class, of the Order of the White Rose of Finland in 2006.
Dr. Jennifer Sealey-Voyksner, ImmunogenX CSO remarks “Dr. Mäki is a world renowned clinician studying celiac disease and has extensive experience in clinical trial design that is key to the future development of our lead therapeutic treatment latiglutenase. Dr. Mäki was the principal investigator for the first efficacy trials for latiglutenase that provided ground breaking results demonstrating histologic protection to a gluten challenge. His knowledge of and faith in latiglutenase gives us great confidence that we will successfully bring this drug to market and help celiac disease patients from the suffering they incur.”
ImmunogenX is preparing for a final Phase 2 trial for latiglutense, an orally administered drug therapy, that is taken with meals and degrades gluten that is inadvertently ingested by individuals with celiac disease maintaining a gluten-free diet.
About ImmunogenX
ImmunogenX (a subsidiary of Immunogenics LLC) is a clinical-stage biotherapeutics company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research. The company is developing Latiglutenase (formerly ALV003) for celiac disease therapy. ImmunogenX is also developing a minimally-invasive diagnostic tool for celiac disease management (CypCelTM) based on a clinically relevant metabolic marker compound that can assess the state of recovery of a celiac patient adhering to a gluten-free diet or other treatment. For food safety, ImmunogenX is pioneering advanced mass spectrometry methods to identify and measure physiologically relevant gluten peptide sequences found in wheat, barley, and rye.
www.immunogenx.com
For further information please contact
Matthew Dickason, COO 949 679-0900 mdickason@immunogenx.com
News Release
Newport Beach, CA – October 12, 2017
